Floatz logo

Car-20/19-T Cells

Mantle Cell Lymphoma (MCL)

Medical College of WisconsinCell therapyPhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Mantle Cell Lymphoma (MCL) cohort.

Asset / SponsorPhaseRating
Rocbrutinib
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 3BB
Zuberitamab
Zhengzhou University
Phase 4B
Ruxolitinib
Ruijin Hospital
Phase 2CCC
Zamtocabtagene Autoleucel
Miltenyi Biomedicine GmbH
Phase 2CCC
Orelabrutinib
Ruijin Hospital
Phase 2CCC

View all 30 →

Same molecule, other indications

Car-20/19-T Cells is also rated in:

non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
Primary Mediastinal Large B-cell Lymphoma (PMBCL)Dormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →